TP53 and myelodysplastic syndrome: Development of news drugs such as VYXEOS, a liposomal formulation of cytarabine and daunorubicin has shown very impressive results in patients with t-AML fit for intensive chemotherapy.34,35 In phase 1b/2 in combination with 5-AZACYTINE, APR-246, a small molecule that selectively induces apoptosis in TP53-mutated cancer cells, showed promising results in unfit TP53 mutated AML/MDS patients.36,37 However, much therapeutic progress has still to be made for TRMN patients.